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The DAN family, including Gremlin-1 and Gremlin-2
(Grem1 and Grem2), represents a large family of
secreted BMP (bonemorphogenetic protein) antago-
nists. However, how DAN proteins specifically inhibit
BMP signaling has remained elusive. Here, we report
the structure of Grem2 bound to GDF5 at 2.9-A˚ reso-
lution. The structure reveals two Grem2 dimers
binding perpendicularly to each GDF5 monomer,
resembling an H-like structure. Comparison to the
unbound Grem2 structure reveals a dynamic N termi-
nus that undergoes significant transition upon com-
plex formation, leading to simultaneous interaction
with the type I and type II receptor motifs on GDF5.
Binding studies show that DAN-family members
can interact with BMP-type I receptor complexes,
whereas Noggin outcompetes the type I receptor
for ligand binding. Interestingly, Grem2-GDF5 forms
a stable aggregate-like structure in vitro that is not
clearly observed for other antagonists, including
Noggin and Follistatin. These findings exemplify the
structural and functional diversity across the various
BMP antagonist families.INTRODUCTION
The bonemorphogenetic proteins (BMPs) and growth and differ-
entiation factors (GDFs) play many pivotal roles in biology, where
their misregulation is central in numerous disease-state pathol-
ogies, including kidney and lung fibrosis, pulmonary arterial hy-
pertension (PAH), and numerous cancers and skeletal diseases
(Bragdon et al., 2011; Brazil et al., 2015). As such, regulation of
BMP signaling is critical during both development and adult
homeostasis.
Extracellular regulation of BMP signaling is dominated by the
action of secreted protein antagonists that function to sequester
BMP ligands and prevent receptor activation. While BMP ligands
show significant structural conservation, their antagonist coun-
terparts are strikingly diverse, ranging from small single-domainCell Re
This is an open access article under the CC BY-Nproteins (e.g., Noggin and the DAN family) to large multi-domain
proteins (e.g., Chordin, Crossveinless-2 [CV2], Follistatin, and
GASP) (Brazil et al., 2015). Despite their importance, the struc-
tural basis of their activity is poorly understood, as only two
BMP-bound antagonist crystal structures have been solved.
These include Noggin in complex with BMP7 and a binding
domain of CV2 in complex with BMP2 (Groppe et al., 2002;
Zhang et al., 2008). In both cases, these antagonists were shown
to compete for both type I and type II receptor binding motifs on
BMP, a common structural theme also identified for Follistatin-
family antagonists (Mueller and Nickel, 2012; Thompson et al.,
2005). However, these antagonist families exhibit vastly different
binding mechanisms and structures, making it difficult to predict
how uncharacterized antagonist families achieve inhibition.
The DAN family includes Gremlin-1 (Grem1) and Gremlin-2
(Grem2 or PRDC), Coco, Cerberus, NBL1 (Dan), USAG-1
(Wise), and Sclerostin (SOST), most of which have been shown
to directly inhibit BMP signaling (Nolan and Thompson, 2014).
Furthermore, members of the DAN family have been directly
linked to various pathologies, including PAH, chronic kidney dis-
eases (CKDs), and cancer, through their interactions with BMPs
(Cahill et al., 2012; Dolan et al., 2005; Gao et al., 2012; Karagian-
nis et al., 2015; Yanagita et al., 2006). In addition, Grem2, which
is well conserved with Grem1 (68% identical), has been linked to
atrial specific cardiomyocyte differentiation and hypertrophy
(M€uller et al., 2013; Tanwar et al., 2014). As such, structure/func-
tion studies of DAN-BMP interactions could help progress our
ability to target these proteins in disease.
Here, we present the crystal structure of Grem2 bound toGDF5
at 2.9-A˚ resolution. Similar to other antagonists, Grem2 binds
both the type I and type II receptor-bindingmotifs onGDF5. How-
ever, unlike other known BMP-antagonist structures, two inde-
pendentGrem2dimers bindperpendicularly to eachGDF5mono-
mer, requiring only one monomer per Grem2 dimer to form this
interaction and forming potential transient and stable complexes
with the binary BMP-type I receptor complex.
RESULTS
Structure of Grem2-GDF5
Previously, we solved the structure of Grem2 and began charac-
terizing how it functionally inhibits BMP signaling (Nolan et al.,ports 16, 2077–2086, August 23, 2016 ª 2016 The Author(s). 2077
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Structure of Grem2-GDF5
(A) Ribbon and surface representations of Grem2-
GDF5 in a ligand-centric view. Grem2 (green,
chain E; blue, chain F); GDF5 (pink, chain A; gold,
chain C).
(B) Schematic of the Grem2-GDF5 complex.
(C) Grem2 in the apo state (left; PDB: 4JPH) or
GDF5-bound state (right).
(D) Superposition of unbound GDF5 (dark purple/
orange; PDB: 1WAQ) and Grem2-bound (pink/
gold). For Grem2 and GDF5 (underscored), F1, F2,
and W correspond to finger 1, finger 2, and the
wrist region, respectively. Dotted lines show un-
resolved amino acids 35–44 in Grem2.2013). To extend these studies, we sought to determine the struc-
ture of Grem2 in complex with BMP. As initial attempts using the
high-affinity ligand BMP2 proved intractable (see Supplemental
Experimental Procedures), we pursued alternative BMP ligands
and readily determined the structure of Grem2 bound to its mod-
erate affinity ligand, GDF5, at a resolution of 2.9 A˚ (Figure 1A; Fig-
ure S1; Table S1).GDF5,while not often studied in light of theDAN
family, is able to bindGrem2with appreciable affinity (dissociation
constant [KD], 146 nM), as compared to BMP2 (KD, 9 nM), when
tested by surface plasmon resonance (SPR) (Figure S2A; Table
S2). While the Grem2-BMP2 structure was desired, we hypothe-
sized that the Grem2-GDF5 structure would prove as useful and
reveal the full extent of the DAN-BMP interaction.
Froma ligand-centric view, thestructure shows that twoGrem2
dimers are found bound perpendicularly to the distal ends of the
GDF5 dimer, generating internal C2 symmetry across the ligand
(Figures 1A and 1B). Interestingly, each Grem2 monomer exclu-
sively interacts with one GDF5 dimer, leaving the opposing
Grem2 monomer open to interact with an additional GDF5 (Fig-
ure 1A). This 2:1 Grem2-GDF5 complex is generated by expand-
ing the asymmetric unit (ASU), which contains two exclusive 1:1
dimer:dimer complexes of Grem2-GDF5 (Figure S1).2078 Cell Reports 16, 2077–2086, August 23, 2016Previously, we showed that the struc-
ture of Grem2 (PDB: 4JPH) exhibits a
growth-factor-like fold, including a central
cysteine-rich domain (CRD), or DAN
domain, which is flanked by N- and C-ter-
minal extensions (Nolan et al., 2013). Us-
ing classical transforming growth factor
b (TGF-b) ligand naming conventions,
the DAN domain is divided into pairs of
long anti-parallel b strands, termed finger
1 (F1) and finger 2 (F2), with a wrist region
(W) that connects the two fingers (Fig-
ure 1C). The structure of Grem2-GDF5 re-
veals that the core domain of Grem2
binds the convex surface of GDF5, using
residues near or within the W of Grem2,
while its N terminus engages the apical
surface of GDF5 and threads into the
concave surface formed by GDF5 dimer-
ization (Figure 1A). Similar to other known
antagonists, Grem2 is found occupyinginterfaces onGDF5, consistent with both the type I (concave sur-
face) and type II (convex surface and knuckle region) receptor-
binding motifs (Figures 1A, 1D, and 3A) (Mueller and Nickel,
2012).
Comparing the unbound and GDF5-bound forms of Grem2 il-
lustrates that a number of structural changes occur upon BMP
binding, despite a root-mean-square deviation (RMSD) of 2.0 A˚
across all Cas. Most noticeably, the N terminus of Grem2 un-
dergoes drastic change upon ligand binding (RMSDs of 8.5 A˚
for the N terminus and 1.4 A˚ for the DAN domain) (Figure 1C).
In the apo state, Grem2 contains a helices that lie over the
DAN domains of the dimer, partially blocking a significant portion
of the BMP binding epitope (Figure 1C) (Nolan et al., 2013). Upon
binding GDF5, these helices mostly disassociate from the DAN
domain to wrap over the fingers of GDF5 and insert into the
concave surface of the ligand (Figures 1A and 1C). This confor-
mational change not only results in contacts between the N ter-
minus of Grem2 and GDF5 but also acts to expose underlying
residues within the W and DAN domain of Grem2 that interact
with the convex surface of the ligand. For GDF5, only slight
structural changes are observed upon Grem2 binding (RMSD
of 0.5 A˚ across all Cas), consistent with the prescribed rigid
and non-flexible nature of BMP subclass ligands (Figure 1D) (Mu-
eller and Nickel, 2012).
Taking a detailed look at the interfaces between Grem2 and
GDF5, four main regions can be described (Figures 2A–2E):
(interface I) the N terminus of Grem2 binding the concave surface
of GDF5 (960 A˚2); (interface II) the N terminus of Grem2 hydrogen
bonding the apical surface of GDF5 at the knuckle region of F2
(230 A˚2); (interface III) theWof Grem2 binding the convex surface
of GDF5 (540 A˚2); (interface IV) the C terminus of Grem2 binding
the F1 loop of GDF5 (310 A˚2); (total buried surface area of
1,822 A˚2). For interface I, hydrophobic residues from the N termi-
nus of Grem2 interact with hydrophobic amino acids on both the
proximal and distal GDF5monomers. In addition, three hydrogen
bonds are formed within this interface, specifically the backbone
amide and carbonyl from A54 and the carbonyl of Y34 from
Grem2 with the N64 side chain and L56 carbonyl of the distal
GDF5monomer (Figure 2B). Interestingly, mutation of this aspar-
agine in GDF5 (N64K) has been linked tomultiple synostosis syn-
drome (SYM1) and loss of Noggin-based inhibition (Seemann
et al., 2009). Additionally, the N-terminal interaction of Grem2
with GDF5 is likely stabilized by interface II, where backbone-
mediated hydrogen bonds form a small b sheet between L60-
R65 in Grem2 and N102-Y106 in GDF5 (Figure 2C).
For interface III, Grem2 again binds GDF5, utilizing extensive
hydrophobic contacts. Here, residues within the W and DAN
domain (F104, I106, and F117) and the N terminus of Grem2
(L60, V61, and V62) interact with the convex hydrophobic sur-
face of GDF5 F2, created by residues I38, L96, V104, and
Y106 (Figure 2D). Lastly, the C terminus of Grem2 interacts
with the helical turn within F1 of GDF5 (interface IV) through hy-
drophobic, polar, and ionic interactions (Figure 2E). Combined,
interfaces III and IV compose a large binding interface between
Grem2 and GDF5 (845 A˚2), likely contributing a large majority
of the Grem2-BMP interaction.
Mutational Analysis of the Grem2 BMP-Binding Epitope
Using the Grem2-GDF5 structure as a model, we wanted to
determine whether the Grem2 interface was consistent between
the low-affinity ligand, GDF5, and the better studied, high-affinity
target of the DAN family, BMP2. We previously identified several
amino acids in Grem2 and NBL1 that are important for BMP2-
mediated inhibition and directly correlated decreases in binding
affinity with decreases in cell- and in vivo-based signaling (Fig-
ure 2F) (Nolan et al., 2013, 2015). Furthermore, these previously
identified amino acids are central to interface III.
While these studies provided insight into the location of the
BMP binding epitope, even the most disrupting mutations in
Grem2 maintained significant activity (Nolan et al., 2013). This
is consistent with the extensive interaction revealed in the
Grem2-GDF5 structure. Therefore, we extended our mutational
analysis to more effectively disrupt these hydrophobic interfaces
by modulating a series of Grem2 residues. As such, we gener-
ated the I106A, I106A/F117A, F104A/F117A, and F104A/I106A/
F117A mutants (interface III) and the I49D/V52D/L53D mutant
(interface I) (Figures 2B and 2D). Previously, we identified F104
and F117 as significant contributors to the BMP interaction,
where mutation of these to alanine gave a 49-fold (3.5-fold in
NBL1) and 63-fold increase in the half maximal inhibitory con-centration (IC50) (or decrease in activity) of Grem2 for BMP2,
respectively, as well as corresponding decreases in binding
KDs as determined by SPR (Nolan et al., 2013, 2015).
Grem2 mutants were tested for their ability to inhibit both
BMP2- and GDF5-based signaling in osteoblast cells stably
transfected with a BMP-responsive promoter (Yadav et al.,
2012). As expected, these mutants significantly decreased the
ability of Grem2 to inhibit both BMP2 and GDF5 signaling, where
this effect increased with the number of mutations introduced
into interface III. For F104A/I106A/F117A, nearly all inhibition
was lost toward both BMP2 and GDF5 (721-fold and 8-fold in-
creases in IC50, respectively) (Figures 2E and S2B; Table S3).
For I49D/V52D/L53D, only minor comparative increases were
seen in IC50 values for BMP2 and GDF5 (2.9-fold and 1.2-fold,
respectively), suggesting that interface I and the N terminus of
Grem2 only modestly contribute to overall BMP-based inhibition
(Figures 2E and S2B; Table S3). Furthermore, these findings are
consistent with amino acid conservation across the DAN family,
as F104, I106, and F117 are mostly conserved across the stron-
ger BMP-antagonizing members (Grem1, Coco, and NBL1) and
poorly conserved in SOST and USAG-1, while I49, V52, and L53
show no significant conservation (Figure S2C).
Next, we tested our Grem2 mutants in developing Xenopus
embryos, which require functional BMP4 and BMP7 signaling
for proper development. Microinjection of BMP antagonists,
such as Grem2, into the developing embryo can inhibit endoge-
nous BMP ligands, resulting in the loss of ventral-posterior struc-
tures (e.g., the tail) and loss of direct BMP-target gene expres-
sion (e.g., sizzled). Our results show that Grem2 mutants at
interface III maintain no ability to inhibit downstream sizzled
expression and tail growth and elongation, as compared to
wild-type, resembling BSA control experiments (Figures 2G
and 2H). This finding correlates well with our luciferase reporter
results for both BMP2- and GDF5-based signaling, suggesting
a generality for Grem2-based BMP inhibition in vitro and in vivo.
Receptor-Based Mechanism of Grem2-Mediated BMP
Inhibition
A growing theme with extracellular BMP antagonists is their abil-
ity to block ligand-receptor interactions, where antagonists
directly interact with surfaces associated with type I and type II
receptor binding (Figures 3A and 3B) (Mueller and Nickel,
2012). To better illustrate this, we colored the surfaces of the
ligand structures and aligned sequences that interact with
Grem2, Noggin, Follistatin, CV2, and the type I and type II recep-
tors (Figures S3A–S3C). This analysis clearly shows that each
antagonist utilizes highly conserved areas consistent with the re-
ceptor-binding motifs on BMP. However, comparison of Grem2
and Noggin depicts very different BMP-binding strategies.
Noggin, a disulfide-bonded dimer, binds on the apical side of
the ligand, simultaneously interacting with all four receptor sites,
whereas two Grem2 molecules, similar to CV2, independently
block each end of the ligand (Figures 3A and 3B). Therefore,
we sought to determine whether Grem2 functionally blocks
type I and type II receptor binding to BMP, similar to Noggin
(Groppe et al., 2002; Zimmerman et al., 1996).
For these experiments, we mixed various ratios of Grem2 and
Noggin with BMP2 (molar ratios of 0.1:1 to 2:1 antagonist toCell Reports 16, 2077–2086, August 23, 2016 2079
Figure 2. Grem2-BMP Binding Interface and Analysis
(A) Grem2-GDF5 complex with BMP-binding interfaces in Grem2 (labeled I through IV) highlighted in green, blue, red, and magenta, respectively.
(B–E) Grem2 and GDF5 are colored as in Figure 1. Zoomed-in view of the Grem2-GDF5 (B) interface I, (C) interface II, (D) interface III, and (E) interface IV, as
described in Results.
(legend continued on next page)
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BMP) and tested their ability to bind to immobilized Alk3-Fc and
BMPR2-Fc receptors using SPR. As shown, Grem2 blocks bind-
ing of BMP2 to BMPR2 at ratios near or greater than 1:1, as ex-
pected based on the extensive Grem2-GDF5 interface III, similar
to Noggin (Figures 3C and S3D). In addition, Grem2 blocked
BMP2 binding to Alk3 at a ratio of 2:1, consistent with the stoichi-
ometry of the Grem2-GDF5 complex (Figure 3D). In contrast,
Noggin only requires a 1:1 ratio to completely block BMP2 bind-
ing to Alk3, consistent with the structure of Noggin-BMP7
(Figure S3E).
To generalize our findings for Grem2 to the rest of the DAN
family, we extended our analysis to the moderate BMP antago-
nist, NBL1. Expectedly, NBL1 blocked BMP2 binding to
BMPR2 similar to Grem2 (Figure 3F). Interestingly, NBL1 did
not block BMP2 binding to Alk3, even at a 2:1 ratio (Figure 3G).
Furthermore, at certain ratios (0.5:1 to 2:1 for NBL1:BMP2 and
even 0.5:1 for Grem2:BMP2), the total response increased as
compared to the BMP2 control, possibly indicating the binding
of DAN-BMP complexes to Alk3 (Figures 3D and 3G). With this
in mind, we wanted to test more directly whether or not Grem2
and NBL1 lacked the ability to block type I receptor binding
and whether potential ternary DAN-BMP-type I receptor com-
plexes were forming.
To test DAN-BMP-type I receptor complex formation, SPR
was performed using immobilized Alk3-Fc. For each experi-
ment, BMP2 was injected to form the binary BMP2-Alk3 com-
plex on the chip, followed by direct injection of Grem2, NBL1,
or Noggin. Unexpectedly, both Grem2 and NBL1 showed a sig-
nificant ability to bind the BMP2-Alk3 complex. While Grem2
showed a relatively fast dissociation rate, NBL1 formed a stable
ternary complex with BMP2-Alk3 (Figures 3E and 3H). This dif-
ference is likely explained by the short N terminus of NBL1,
which lacks the length necessary to traverse into the type I re-
ceptor-binding motif of BMPs (Nolan and Thompson, 2014).
Interestingly, the binding of Grem2 and NBL1 never drops
below the response level of ligand binding alone, suggesting
that a transient (Grem2) or stable (NBL1) inhibitory DAN-
BMP-type I receptor complex can form (Figures 3E and 3H).
In contrast, Noggin binding to the BMP2-Alk3 complex dissoci-
ates very rapidly, where the generated response drops well
below the levels for BMP2 binding alone, suggesting that
Noggin strips BMP2 away from Alk3 (Figure 3I). In addition,
each antagonist (Grem2, NBL1, and Noggin) showed no ability
to form a potential ternary complex with BMP2 and BMPR2,
likely due to the rapid dissociation of the BMP2-BMPR2 com-
plex (Figure S3F).
Next, we wanted to determine whether the SPR response
following Noggin treatment (as mentioned earlier) could be
restored to that of the BMP2 alone binding to Alk3. This injection
caused the response curves to closely match those of the initial
BMP2 injection, suggesting that Noggin removed the majority of
BMP2 from Alk3 (Figure 3J). For Grem2 and NBL1, injection of(F) BMP-responsive luciferase reporter assay using a BMP-responsive osteoblas
Experiments were performed in triplicate. Error bars indicate mean ± SEM. WT,
(G and H) Injection (stage 9) of wild-type and Grem2 mutants (0.5 mM, 1 mM, and
images (H, top) of BMP-dependent axial development (stage 35). (H, bottom) In sit
Numbers in boxes indicate the concentration of the reagent used (top and bottoadditional BMP2 resulted in a higher maximal response when
compared to BMP2 alone (Figure 3J). This heightened response
is dependent upon prior injection of Grem2 or NBL1 and sug-
gests formation of a DAN-BMP-type I receptor complex.
Lastly, we recapitulated our SPR findings using an ELISA-
based assay. For these experiments, Alk3-Fc was immobilized.
Fluorescently labeled BMP2 was then added to wells containing
Alk3-Fc and incubated, and excess ligand was washed away.
Wells were then treated with either Grem2 or Noggin, and fluo-
rescence was measured in the supernatant to determine
whether BMP2 was dissociating from Alk3-Fc. As expected,
Grem2 did not significantly increase the amount of BMP2 in
the supernatant (Figure 3K). However, Noggin drastically
increased the levels of BMP2 in the supernatant, supporting
the hypothesis that Noggin can remove BMP2 from Alk3
(Figure 3K).
Grem2-BMP Ordered-Aggregate Formation
In the Grem2-GDF5 structure, one monomer of Grem2 interacts
with one dimer of GDF5, leaving the opposing Grem2 monomer
open to bind another GDF5 ligand. Upon generating symmetry
outside of the ASU, a larger, alternating, and ordered-aggre-
gate-like structure is formed between Grem2 and GDF5, where
each monomer propagates to a new interaction partner, seem-
ingly ad infinitum, and possibly explaining the extreme insolu-
bility of purified Grem2-BMP complexes (Figure 4A; see Supple-
mental Experimental Procedures).
To test whether this alternating aggregate could be pro-
duced in vitro, we utilized SPR. First, we injected Grem2 over a
BMP2 amine-coupled chip to form the Grem2-BMP complex,
followed by additional alternating injections of Grem2 and
BMP2. Agreeing with our structure, these alternating injections
resulted in a continuously additive binding response, illustrating
the ordered-aggregate-like nature of this interaction (Figure 4B).
Furthermore, this response is dependent upon alternation of
Grem2 and BMP2, where Grem2 followed by Grem2, or BMP2
followed by BMP2, could not recapitulate this effect (Figure S4).
NBL1 also exhibits this ordered-aggregate-like formation when
tested with BMP2, albeit less efficiently (Figure 4B). Additionally,
recent evidence suggests a similar mechanism for Grem1
and BMP2 using assays synonymous to SPR (Kisonait _e et al.,
2016).
Next, we performed a similar analysis with Follistatin and
Noggin. Not surprisingly, Follistatin did not exhibit any ordered
aggregation with Activin A (Figure 4E). For Noggin, however,
this effect was observed to some degree (Figure 4C). Despite
this, the off rate of Noggin in this state was much faster as
compared to Noggin alone with BMP2. Taking into account
that Noggin exists as a functional dimer, it is not surprising to
find some, albeit likely unfavorable, ability to form these larger or-
der complexes (Groppe et al., 2002). To directly compare Noggin
and Grem2, we performed injections at a slower flow rate witht cell line and showing titration of various Grem2 mutants against 2 nM BMP2.
wild-type.
10 mM) in developing Xenopus embryos. Quantification (G) and representative
u hybridization (stage 20) for mRNA expression of the BMP-target gene sizzled.
m), as well as the number of embryos scored (bottom).
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Figure 3. Differences in Antagonist Inhibition of Ligand-Receptor Interactions
(A and B) Structures of BMP-antagonist and BMP-receptor complexes.
(C, D, F, and G) SPR experiments injecting mixtures of (C and D) Grem2-BMP2 and (F and G) NBL1-BMP2 onto Alk3-Fc or BMPR2-Fc, captured using a protein A
chip. Molar ratios 0.1:1, 0.5:1, 1:1, and 2:1 of antagonist:ligand were tested. BMP2 was maintained at a constant 250 nM.
(legend continued on next page)
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longer association/dissociation times for three consecutive
alternating injections of ligand and antagonist. Although both
proteins form higher order aggregates, the maximal response
for each alternating Grem2 and BMP2 injection remains highly
sustained, while those for Noggin and BMP2 show a decreasing
trend with each subsequent injection (Figure 4D). This suggests
chain-growing as a non-ideal, thermodynamically unfavorable
mechanism for Noggin inhibition but very likely for Grem2 in
the in vitro context (Figure 4D).
DISCUSSION
In this study, we present the structure of Grem2 bound to GDF5.
Through analysis of this structure, numerous features have been
revealed, distinguishing the DAN family of BMP antagonists from
other ligand-antagonist structures (e.g., CV2-BMP2, Noggin-
BMP7, Follistatin-Activin A) (Groppe et al., 2002; Thompson
et al., 2005; Zhang et al., 2008). Furthermore, the Grem2-GDF5
structure supports the theme that structurally diverse families
of antagonists have evolved to recognize structurally conserved
BMP ligands.
Analysis of the Grem2-GDF5 structure reveals a number of
features consistent with our previous findings, such as the
importance of F104 and F117 inGrem2-based BMPantagonism,
where we directly correlated decreases in binding to losses in
cell-based and in vivo signal inhibition (Nolan et al., 2013).
Furthermore, this structure has revealed the full extent of the
BMP-binding interface, where four main interfaces can be
described (Figure 2). In our analysis, we found that mutation of
F104, I106, and F117, central to interface III, significantly
reduced the ability of Grem2 to inhibit both BMP2 and GDF5
signaling (Table S3). Unexpectedly, the Grem2-GDF5 structure
shows that Grem2 utilizes both its N- and C-termini to bind
GDF5 and stabilize the complex through both hydrophobic and
polar interactions.
Like other known BMP-binding partners, the N terminus of
Grem2 forms numerous intimate contacts with the concave sur-
face of GDF5. As such, a pivotal ‘‘knob-in-hole’’ feature has been
described for BMP binding to Alk3 (F85), Noggin (P35), and CV2
(I2) (Groppe et al., 2002; Keller et al., 2004; Zhang et al., 2008).
Similarly for Grem2, L53 is positioned within this same hydro-
phobic cleft on GDF5 (Figure 2B). However, this residue, among
others in interface I, does not appear to play a significant role in
BMP signal antagonism, as the I49D/V52D/L53D mutant ex-
hibited near-wild-type activity (Table S3).
Similar to other antagonists, Grem2 engages BMP through
using its receptor-binding motifs (Figure 3 and S3). Further-
more, CV2, Noggin, and Grem2 all utilize N-terminal extensions
to traverse the apical surface of the ligand to extend into the
type I receptor-binding motif (Groppe et al., 2002; Zhang(E, H, and I) SPR experiments using immobilized Alk3. BMP2 (500 nM) was first inj
subsequently titrated (0–3 mM) and co-injected following BMP2. Conc., concent
(J) SPR performed as in (E), (H), and (I), with an additional BMP2 injection to dete
(K) ELISA binding assay using immobilized Alk3-Fc treated with labeled BMP2
concentrations for 1 hr. Fluorescence was measured in the supernatant to quant
Student’s t test; ns, not significant. All experiments were performed in triplicate.
(L) Schematic showing potential DAN-BMP type I receptor ternary complexes.et al., 2008). However, SPR analysis shows that, unlike Noggin,
Grem2 possibly forms a transient DAN-BMP-type I complex,
similar to that seen for Follistatin and BMP4 (Figures 3E and
3I) (Iemura et al., 1998). NBL1 shares this characteristic with
Grem2, although the dissociation is much slower, indicating a
more stable ternary complex (Figures 3E and 3H). This is
possibly due to the short N terminus in NBL1, which likely
cannot traverse into the concave epitope of BMP (Nolan and
Thompson, 2014). In addition, Cerberus has recently been
shown to block Nodal binding to its type II receptor, similar to
Grem2 and NBL1. Differently, Cerberus also blocks ligand-
type I receptor binding, where processing of its extraordinarily
long N terminus may function to modulate its ability to inhibit
specific ligand-receptor-binding events (Aykul and Martinez-
Hackert, 2016). As such, future studies should aim at deter-
mining the role of the variable DAN-family N terminus in the
inhibition of ligand-receptor interactions, if DAN-BMP-type I re-
ceptor complexes exist in the physiological context, and what
impact these complexes exert on BMP signaling, such as a
dominant-negative effect on signaling.
Based upon the similarity of the apo-Grem2 dimer structure
to that of NBL1 and the recently solved structure of Grem1, we
hypothesize that conserved epitopes are utilized across the
DAN family to inhibit BMPs (Kisonait _e et al., 2016; Nolan
et al., 2013, 2015). Physiologically, Grem1 is the most well
studied of all DAN-family antagonists and has been shown
to be critical in numerous aspects of mammalian biology
and disease (Brazil et al., 2015). To extend our structural anal-
ysis to Grem1, we generated models of the Grem1-BMP2 and
Grem2-BMP2 complexes. These models strongly correlate
with our present findings, showing that the type II interface
of BMP2 is central to the interaction and nearly identical
with that seen for Grem2-GDF5 (Figures S3D–S3K). As ex-
pected, F104, I106, and F117 (F125, I127, and F138 in
Grem1) are central in this predicted interface, suggesting a
conserved mechanism for Grem1- and Grem2-mediated inhi-
bition of both GDF5 and BMP2. Consistent with this, it was
recently shown that specific amino acids at the BMP2 type II
interface are important for Grem1 binding (Kisonait _e et al.,
2016).
Further diversifying the Grem2-GDF5 structure from those of
Noggin, CV2, and Follistatin is the ability of this complex to prop-
agate and form ordered-aggregate-like structures in vitro, a
notion supported though our structural and SPR analyses (Fig-
ure 4). As one monomer of Grem2 directly interacts with one
pair of type I and type II motifs on the GDF5 dimer, this leaves
the adjacent Grem2 monomer open to bind an additional
GDF5 ligand (Figure 4A). Our data also indicate that NBL1 ex-
hibits this phenotype, albeit to a lesser degree (Figure 4B).
Recent studies also suggest that Grem1 can form oligomericected to form the Alk3-BMP2 complex. Grem2 (E), NBL1 (H), or Noggin (I) were
ration.
rmine whether ligand binding could be recovered.
, washed, and then treated with Grem2 (blue) or Noggin (orange) at various
ify BMP2 release from Alk3. Error bars indicate mean ± SEM. **p < 0.05 using
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Figure 4. Alternating Aggregation of Grem2-BMP
(A) Grem2-GDF5 complex, colored as in Figure 1, forms a continuous alternating complex extending beyond the ASU.
(B–D) SPR co-injection studies of antagonist and BMP2 over immobilized BMP2. Antagonists were injected followed by alternating injections of BMP2 and
antagonist (all at 500 nM). Control experiments show consecutive injections of antagonist. (B and C) Analysis of (B) Grem2 and NBL1 and (C) Noggin. (D) Direct
comparison of Grem2 and Noggin at a slower flow rate with a longer association time.
(E) Similar SPR experiment with immobilized Activin A and alternating injections of Follistatin and Activin A. Tic marks and labels show specific protein and time of
injection.complexes when binding to BMP2 (Kisonait _e et al., 2016). It
will be interesting to determine whether this mechanism is
generally consistent across the DAN family. Furthermore, future
studies should aim to verify the existence of these alternating
higher order aggregates in vivo, perhaps through the use of su-
per-resolution confocal microscopy. In addition, if DAN-family
heterodimers can be generated (e.g., a half wild-type and half
binding-deficient mutant), this would allow for the exploration2084 Cell Reports 16, 2077–2086, August 23, 2016of the necessity and the mechanistic role of these aggregation
events in BMP signal inhibition.
In conclusion, the structure of Grem2-GDF5 has revealed a
number of key findings for DAN-family-mediated BMP inhibition.
These findings increase our general understanding of DAN-fam-
ily-mediated BMP inhibition and reveal how structurally diver-
gent antagonists have evolved unique mechanisms to inhibit
BMP ligands.
EXPERIMENTAL PROCEDURES
Protein Expression and Purification
Purified Grem2, GDF5, BMP2, NBL1, and Follistatin were generated utilizing
previously published protocols (Cash et al., 2009; von Einem et al., 2010; Nolan
et al., 2013, 2015). Grem2mutantswere generated using theQuikChange Site-
Directed Mutagenesis Kit and produced similar to wild-type Grem2. All other
protein components utilized for SPR or other experiments were purchased
from R&D Systems.
X-Ray Structure Determination and Refinement of Grem2-GDF5
Grem2 andGDF5 were mixed in 10mMHCl and concentrated to 10mg/ml in a
2:1 molar ratio. Grem2-GDF5 crystals were grown by hanging drop vapor
diffusion using 100 mM HEPES (pH 7.5), 1.4 M NH4Cl, 4% ethylammonium
nitrate, at 20C. Diffraction data were collected at the Advanced Photon
Source (23-ID-D), Argonne National Laboratory. Initial phases were generated
by molecular replacement using Phaser with the structures of Grem2 (PDF:
4JPH) and GDF5 (PDF: 1WAQ). Refinement was performed using Phenix
with noncrystallographic symmetry (NCS). See the Supplemental Experi-
mental Procedures for details.
SPR
All experiments were performed similarly to the procedure previously
described (Nolan et al., 2013). Briefly, BMP2, BMP4 (RnD), BMP7 (RnD),
GDF5, Alk3-Fc (RnD), BMPR2-Fc (RnD), and Activin A (RnD) were immobilized
to the surface of a CM5 sensor chip. For receptor-binding experiments, protein
Awas immobilized, followed by the capture of Alk3-Fc or BMPR2-Fc, or recep-
tors were directly coupled. See the Supplemental Experimental Procedures for
details.
Luciferase Reporter Assays
A BMP-responsive luciferase reporter osteoblast cell line, kindly provided by
Dr. Amitabha Bandyopadhyay, was used to measure BMP activity, as previ-
ously reported (Nolan et al., 2015). Cells were grown overnight in a 96-well
plate, treated with DMEM/high glucose for 4 hr, and then treated with proteins
for 3 hr and monitored for luminescence. IC50 values were calculated using
Prism GraphPad.
Xenopus Embryo Assay
Embryo manipulations and microinjections were performed as previously
described and staged according to the normal table of development
for Xenopus laevis (Nolan et al., 2013). Xenopus experiments were
performed in compliance with ethical regulations outlined by the NIH and
institutional guidelines under Cincinnati Children’s Hospital Medical Center
Institutional Animal Care and Use Committee (IACUC) approved protocol
3C10067. Xenopus laevis animals were of 1–3 years of age. See the Sup-
plemental Experimental Procedures for details.
ELISA Competition Assay
Alk3-Fc was immobilized to a 96-well ELISA plate at a concentration of
5 mg/ml. BMP2 was labeled using carboxyrhodamine (Molecular Dimensions,
BMP2*). BMP2* was incubated with immobilized Alk3-Fc for 1 hr at 1.5 mg/ml,
washed with PBS, and then incubated for 1 hr with either Noggin or Grem2.
Supernatant was then removed from each well and analyzed for fluorescence
(BioTek Synergy H1). Controls included PBS alone, BMP2* alone, and BMP2*
incubated with Alk3 for comparison.
Statistical Methods
Statistical significance was determined using the Student’s t test. All grouped
data are represented as the mean ± SEM. All data collection for each experi-
ment was performed, at a minimum, in triplicate to ensure reproducibility.
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